Artificial intelligence (AI) is set to transform the care of women with cancer. From early detection via digital phenotyping ...

A deep spatial proteomic analysis of healthy fallopian tube epithelium, matching high-grade serous ovarian cancer (HGSOC) ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

“These results highlight potential mechanisms by which loss of p53 function contributes to an immunosuppressive microenvironment in HGSC, and provide insight into ...

Nov. 7, 2024 -- Ovarian cancer is often called the “silent killer” for a reason: its early symptoms can be subtle, making it easy to mistake for other conditions. But being proactive about our health ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

Ovarian cancer is an abnormal growth of cells or tumors in the ovaries. Some forms of ovarian cancer are more aggressive than others, like high-grade serous ovarian cancer, which is common and ...

Abstract: Epithelial ovarian cancer is an aggressive form of gynecologic malignancy that significantly contributes to morbidity and mortality rates among women globally. Effective diagnosis and ...

Ovarian cancer management is challenging due to high morbidity and mortality, often from late-stage diagnoses. Advances in tumor genomics have led to targeted therapies, improving outcomes for ...

Current CA-125 thresholds may miss ovarian cancer in racially diverse patients, delaying treatment initiation and contributing to health disparities. Original CA-125 studies were conducted on ...

The combination of relacorilant and nab-paclitaxel improved progression-free and overall survival in patients with platinum-resistant ovarian cancer. Relacorilant combined with nab-paclitaxel ...

Ovarian-type serous adenocarcinoma of the testis is an extremely rare malignant disease, and experience and evidence regarding its treatment are lacking. Herein, we describe the case of a 39-year-old ...